1. Home
  2. SRPT vs LASR Comparison

SRPT vs LASR Comparison

Compare SRPT & LASR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • LASR
  • Stock Information
  • Founded
  • SRPT 1980
  • LASR 2000
  • Country
  • SRPT United States
  • LASR United States
  • Employees
  • SRPT N/A
  • LASR N/A
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • LASR Semiconductors
  • Sector
  • SRPT Health Care
  • LASR Technology
  • Exchange
  • SRPT Nasdaq
  • LASR Nasdaq
  • Market Cap
  • SRPT N/A
  • LASR N/A
  • IPO Year
  • SRPT 1997
  • LASR 2018
  • Fundamental
  • Price
  • SRPT $36.27
  • LASR $11.67
  • Analyst Decision
  • SRPT Buy
  • LASR Strong Buy
  • Analyst Count
  • SRPT 23
  • LASR 4
  • Target Price
  • SRPT $131.09
  • LASR $15.13
  • AVG Volume (30 Days)
  • SRPT 4.0M
  • LASR 298.2K
  • Earning Date
  • SRPT 05-06-2025
  • LASR 05-08-2025
  • Dividend Yield
  • SRPT N/A
  • LASR N/A
  • EPS Growth
  • SRPT N/A
  • LASR N/A
  • EPS
  • SRPT N/A
  • LASR N/A
  • Revenue
  • SRPT $2,233,371,000.00
  • LASR $205,689,000.00
  • Revenue This Year
  • SRPT $64.51
  • LASR $8.26
  • Revenue Next Year
  • SRPT $22.40
  • LASR $10.40
  • P/E Ratio
  • SRPT N/A
  • LASR N/A
  • Revenue Growth
  • SRPT 59.15
  • LASR 2.66
  • 52 Week Low
  • SRPT $35.46
  • LASR $6.20
  • 52 Week High
  • SRPT $173.25
  • LASR $14.73
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 22.68
  • LASR 79.70
  • Support Level
  • SRPT $35.46
  • LASR $7.88
  • Resistance Level
  • SRPT $64.80
  • LASR $8.60
  • Average True Range (ATR)
  • SRPT 3.78
  • LASR 0.40
  • MACD
  • SRPT -1.64
  • LASR 0.36
  • Stochastic Oscillator
  • SRPT 2.76
  • LASR 98.29

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: